Drugs / AZD0186
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05694741 | Dec 2022 → May 2023 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0186 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05694741 ↗ |
| Route | Oral | “Subjects will receive AZD0186 orally.” NCT05694741 ↗ |